Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...

Jubilant Pharmova announced its US subsidiary, Jubilant HollisterStier LLC, underwent a USFDA inspection. The facility in Spokane, Washingt...

Easing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Indian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...

Market expert Sunil Subramaniam advised caution amid geopolitical uncertainty and rising input costs, while favouring consumer durables, ca...

Benchmark indices experienced a negative close on Thursday, marked by volatile trade and profit booking. Analysts anticipate the Nifty to c...

Domestic equities closed marginally lower due to weakness in financial and consumer shares, despite gains in IT stocks. Analysts suggest th...

Markets extended their rebound for a second consecutive session on Thursday, buoyed by supportive global cues and selective buying in heavy...

Markets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...

Indian stocks might open higher next week. GIFT Nifty showed a strong rise Friday morning. Investors are watching oil prices and global eve...

Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...

The committee is supposed to submit its report in 90 days. It has been tasked to examine the provisions of stakeholder departments with res...

The promoters are obligated to hold a minimum 26 per cent shares and management control of Torrent Pharma during the period of loans the co...

Margin fell to 22.6 per cent compared with 27.8 per cent in the same quarter last year.

The agreement will help bring cost effective and quality drugs to patients in China.

Aurobindo Pharma said that it is "confident of addressing these issues within the stipulated timeline".